Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)

 

More Info on the Correlation of Rash with Outcome on EGFR Inhibitors: My Changing View in Light of the TOPICAL Trial

Please Note: New Treatments Have Emerged Since this Original Post
Author
Howard (Jack) West, MD

There's been a theme with the inhibitors of the epidermal growth factor receptor (EGFR) -- both oral tyrosine kinase inhibitors (TKIs) and IV monoclonal antibodies -- that the patients who demonstrate good results with these agents tend to get a rash, while the patients who don't get a rash do poorly.  We've even got an FAQ discussion of the association of rash and outcome on EGFR inhibitor therapy. That result has been seen in post-hoc analyses of the results in several trials, and not just in lung cancer, but I've been very reluctant to use this concept in my own clinical decision making. Why? A number of reasons. These are just a post-hoc analyses. Tarceva (erlotinib) is FDA approved for all previously treated patients with advanced NSCLC.  You need to try the drug to know if a patient is going to get a rash.  And importantly, some patients do extremely well with EGFR inhibitors despite not developing skin side effects.

Nevertheless, the recent results from the TOPICAL study, just published in the journal Lancet Oncology, adds more firepower to the argument that the question of whether a patient on an EGFR inhibitor develops a rash should be a factor in deciding whether to continue it. Specifically, the results suggest that patients who don't develop a rash in the first month on Tarceva do worse than the patients on placebo . Here's a brief video that describes the work:

[powerpress]

So here's my question: if you or someone you care for were inclined to try Tarceva but didn't develop a rash, would you stop it after a trial period of four weeks or so, or would you still want to refill the prescription for another month or two before a scan clarifies whether there is progression or not?  Would you accept the concept that the development of rash may distinguish between those helped and those potentially even harmed from an EGFR inhibitor?

I think it may be time for me to update my perspective on the FAQ.

Next Previous link

Previous PostNext Post

Related Content

Image
Trial data ASCO 2024
Video
In this video series from ASCO 2024, Drs. Aakash Desai and Fauwzi Abu Rous discuss trial dates and clinical data as presented at the 2024 ASCO. To watch the complete playlist, click here.         
Image
Bladder Cancer Video Library 2024
Video
Dr. Petros Grivas discusses intravesical treatment for patients with nonmuscle invasive, or early-stage, bladder cancer, the importance of participating in clinical trials for bladder cancer, combination therapy options for patients with metastatic or incurable bladder cancer, and the importance of family history of cancer and discussing that history with your doctor.
Image
Case Based Panel
Video
The panel discusses treatment options for a patient diagnosed with EGFR Exon 19 Deletion NSCLC and examines data from the Laura Trial, a patient with a smoking history and diagnosis of small cell lung cancer, and how the Adriatic Study factors into decisions, and a patient with NSCLC adenocarcinoma, and a EGFR Exon 21 L858R Alteration, and how data from the Flaura 2 Trial can impact treatment decisions.

Forum Discussions

Hi elysianfields and welcome to Grace.  I'm sorry to hear about your father's progression. 

 

Unfortunately, lepto remains a difficult area to treat.  Recently FDA approved the combo Lazertinib and Amivantamab...

Hello Janine, thank you for your reply.

Do you happen to know whether it's common practice or if it's worth taking lazertinib without amivantamab? From all the articles I've come across...

Hi elysianfields,

 

That's not a question we can answer. It depends on the individual's health. I've linked the study comparing intravenous vs. IV infusions of the doublet lazertinib and amivantamab...

Recent Comments

JOIN THE CONVERSATION
I could not find any info on…
By JanineT GRACE … on
Hi elysianfields,

 

That's…
By JanineT GRACE … on
Hello Janine, thank you for…
By elysianfields on
EGFR
By happybluesun on